Untitled
1. DENOMINAZIONE DEL MEDICINALE Prasugrel Teva 5 mg compresse rivestite con film Prasugrel Teva 10 mg compresse rivestite con fi
DETERMINAZIONE DEL DIRETTORE DI AREA *
A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease - Journal of Allergy and Clinical Immunology
PRASUGREL TEVA 10 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG, 28 (28 x1) comprimidos. Precio: 33.41€.
ELENCO DPC 15.05.2020 PRINCIPIO ATTIVO (version 2)
A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease - Journal of Allergy and Clinical Immunology
A Reconciliation Attempt of the Acute Coronary Syndrome Clinical Trials on Clopidogrel, Prasugrel, and Ticagrelor
EP2003136A1 - Process for producing high-purity prasugrel and acid addition salt thereof - Google Patents
AO Brotzu
US9012641B2 - Crystalline forms of Prasugrel salts - Google Patents
A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease - Journal of Allergy and Clinical Immunology
C B G Summary Public Assessment Report Generics Prasugrel Teva 5 mg and 10 mg, film-coated tablets (prasugrel) NL/H/4112/001-
Prasugrel Teva 5 mg Prasugrel Teva 10 mg
Appendix C NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Single Technology Appraisal (STA) Vorapaxar for the second
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Single Technology Appraisal (STA) Ticagrelor for the treatment of acute co
A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease - Journal of Allergy and Clinical Immunology
Allegato fabbisogni AOU SS.xlsx
PLAVIX ® - Foglietto Illustrativo
